Scil Proteins establishes business development organisation in California
To be headed by Garry Merry
Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies, Isogenica and TerraSep. He has also held senior executive positions at life science companies including Waters, Applied Biosystems and Qiagen.
‘A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,’ said Frank Ubags, chief operating officer of Scil Proteins. ‘With his background in protein engineering and separations, Garry is ideally positioned to help us achieve our growth objectives.’
Scil Proteins’ Affilin drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the company’s headquarters in Halle, Germany. The corporate headquarters will also remain responsible for all other activities related to the company’s CMO business outside the US and Canada.
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target